logo-loader
viewPropanc Biopharma Inc

Propanc Biopharma appoints Ralf Brandt to scientific advisory board as it develops cancer patent

Propanc Biopharma Inc (OTCMKTS:PPCB) chief executive officer James Nathanielsz speaks to Procative Investors about the company's recent appointment of Dr Ralf Brandt to its scientific advisory board.
 
The company is developing patents for cancer treatment that focuses on solid tumours, using its lead product PRP, and recently received a notice of allowance for its US patent formula. 
 
Nathanielsz says: "This is quite an exciting development because in the US, biologicals, especially ones that are naturally derived, are quite often hard to patent.
 
"We've been able to identify claims that we believe were novel and inventive and the US Patent and Trademark Office agreed - this is probably the highest level of protection needed in the biggest market in the world."

Quick facts: Propanc Biopharma Inc

Price: 0.3605 USD

OTCMKTS:PPCB
Market: OTCMKTS
Market Cap: $421.79 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Emmerson Resources discusses recent diamond drilling...

Emmerson Resources Ltd (ASX:ERM) managing director and CEO Rob Bills updates Proactive on the first diamond drilling activities at the Whatling Hill Project in NSW.  A 1,500-metre reverse circulation (RC) and diamond drilling program is targeting an interpreted porphyry copper-gold...

20 hours, 47 minutes ago

2 min read